Please login to the form below

Not currently logged in
Email:
Password:

Chlamydia test approved for use in EU

A new test for chlamydia, produced by pharmaceutical company Roche, has received CE Mark certification, allowing it to be sold in the EU for clinical use
A new test for chlamydia, produced by pharmaceutical company Roche, has received CE Mark certification, allowing it to be sold in the EU for clinical use.

Chlamydia trachomatis is the most commonly diagnosed STI in England, with approximately two-thirds of cases affecting younger age groups. The infection often has no obvious symptoms and left undetected it will not only continue to be spread through the community, but can also lead to complications such as pelvic inflammatory disease or infertility in women.

"Unexpected mutations in the DNA of an infectious agent such as chlamydia can disrupt laboratory testing and, by extension, proper treatment of patients," said Dr Teresa L. Wright, OBE, chief medical officer at Roche Molecular Diagnostics.

This test, known as COBAS TaqMan CT Test v2.0, differs from other tests as it uses a dual target approach helping to ensure reliability even when mutations occur within the bacteria's DNA.

Using specifically designed analysis equipment, results can be obtained just two and a half hours after a sample is prepared.

13th June 2008

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Videum Health

Videum Health is a premium video platform that offers brands innovative engagement strategies to reach targeted healthcare audiences on a...

Latest intelligence

Report: Achieving launch excellence in the challenging healthcare markets of today
Our in-depth report is based on original data and expert interviews, which coupled with our own experience, ensures we give you the best recommendations for achieving launch success in challenging...
What is blockchain and why should i care - Richard Springham
Four Health - Emerging Technologies The power of blockchain lies in the fact it can prove that a unique event occurred at a certain time with out the need to...
NHS medicines optimisation milestone
Steve How, Paul Midgley and Oli Hudson, of the Wilmington Healthcare Consulting Team, explore the implications of Adalimumab’s recent European patent expiry...

Infographics